Ephedrine
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Ephedrine: From Known Decongestant Use to Nasal Cavity Disease
One-Sentence Summary
Ephedrine is a sympathomimetic (α/β-adrenergic agonist) drug with a long history of use as a nasal/mucosal decongestant, though formal original-indication registration data was not available in this evidence pack. The TxGNN model predicts it may be effective for Nasal Cavity Disease, with 18 clinical trials and 8 publications currently identified, though most show only moderate-to-low direct relevance to Ephedrine itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no SAHPRA licence records on file; historically used as a mucosal decongestant/vasopressor based on known pharmacology |
| Predicted New Indication | Nasal Cavity Disease |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L3 (Observational studies / review-level evidence) |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is flagged as a data gap in this evidence pack (DG002). Based on known pharmacology, ephedrine is a mixed α/β-adrenergic receptor agonist. Its classic effect on the nasal mucosa is vasoconstriction, which reduces mucosal congestion and oedema — the same pharmacological family as pseudoephedrine and phenylpropanolamine, both established nasal decongestants.
This means the TxGNN prediction of “Nasal Cavity Disease” is not a novel mechanistic hypothesis but rather a restatement of an already well-established pharmacological effect of ephedrine. The supporting literature (e.g., PMID 11345158, comparing oral/topical decongestant effects of phenylpropanolamine and d-pseudoephedrine; PMID 14211229, an early clinical trial of ephedrine hydrochloride in the nasal cavity) reinforces that adrenergic agonists of this class have a long track record in nasal congestion management.
However, because ephedrine currently has no SAHPRA registration or licensed formulation in South Africa, and formal safety labelling data (warnings/contraindications) is also a blocking gap (DG001), the mechanistic plausibility alone is not sufficient to support near-term clinical use in this market.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00562120 | Phase 2 | Completed | 21 | Double-blind, double-dummy, 4-way crossover study of an H3-antagonist decongestant vs. nasal allergen challenge in seasonal allergic rhinitis (design analogous to decongestant trials; drug identity vs. ephedrine unconfirmed — relevance grade B) |
| NCT06010316 | N/A | Unknown | 200 | Prospective cohort study of surgical treatment for chronic rhinosinusitis; no drug intervention, disease-domain overlap only |
| NCT03725956 | N/A | Unknown | 30 | Endoscopic sinus surgery effects on sleep disorder in nasal polyposis patients; non-pharmacological |
| NCT00939393 | N/A | Completed | 72 | Endoscopic sinus surgery performed in-office vs. operating room; non-pharmacological |
| NCT00015795 | Phase 1 | Completed | 30 | Laryngeal airflow study in abductor spasmodic dysphonia; low relevance to nasal decongestion mechanism |
| NCT04645511 | N/A | Recruiting | 120 | Placebo-controlled trial of balloon sinuplasty efficacy in chronic/recurrent maxillary rhinosinusitis; device-based, non-pharmacological |
| NCT05494346 | N/A | Recruiting | 101 | Safety/performance study of a decongestant seawater spray with essential oils; medical device, not ephedrine |
| NCT04048174 | N/A | Completed | 27 | Probiotic (Lactococcus lactis) nasal/sinus treatment for chronic rhinosinusitis; unrelated to ephedrine |
| NCT06580210 | N/A | Recruiting | 114 | Performance/safety study of a mechanical decongestant seawater spray with essential oils; medical device |
| NCT03979209 | Phase 1 | Completed | 16 | Cortisol suppression risk with high-volume nasal mometasone irrigation; different drug class, disease-domain overlap only |
Note: Of the 18 trials identified for this indication, only NCT00562120 received a “moderate relevance” (Grade B) assessment; the rest are Grade C (low relevance, mostly surgical/device studies) or ungraded (“pending”). An additional 8 lower-priority/ungraded trials were excluded from this table for space; full list available in the source evidence pack.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11345158 | 2001 | Cohort | American Journal of Rhinology | Compared oral/topical decongestant effects of phenylpropanolamine and d-pseudoephedrine using acoustic rhinometry — same adrenergic-agonist class as ephedrine |
| 14211229 | 1964 | Cohort | Svenska Läkartidningen | Early clinical testing of N-hydroxyethylpromethazine chloride combined with ephedrine hydrochloride in the nasal cavity |
| 12962193 | 2003 | Review | American Journal of Rhinology | Dog model of allergic nasal congestion using acoustic rhinometry (methodology paper) |
| 12387934 | 2002 | Review | Journal of Pharmacological and Toxicological Methods | Pharmacological characterization of a chronic dog model for nasal decongestant mechanism studies |
| 11895194 | 2002 | Review | American Journal of Rhinology | Acoustic rhinometry dog model for nasal congestion studies |
| 11789239 | 2000 | Cohort | Chinese Journal of Integrated Traditional and Western Medicine | Preliminary clinical observation of a rhinitis spray for chronic rhinitis treatment |
| 8283338 | 1993 | Review | Nihon Jibiinkoka Gakkai Kaiho | Case series and concept review of congenital nasal stenosis (10 cases), including intranasal treatment approaches |
| 1541887 | 1992 | Cohort | Journal of Laryngology and Otology | Comparison of pre-operative nasal packing vs. spraying |
Note: None of the identified literature has been individually relevance-graded (“pending”) except by association with the mechanistic rationale; two records (PMID 11345158 and 14211229) most directly involve adrenergic decongestants or ephedrine itself.
South Africa Market Information
Ephedrine currently has no SAHPRA product registrations on file (total licences: 0; market status: Not marketed). No dosage forms, brand names, or approved indication text are available for this drug entity in South Africa.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
(No structured warnings, contraindications, or drug-drug interaction data were available in this evidence pack — this is flagged as a Blocking data gap (DG001) pending retrieval of TFDA/PI labelling documents.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- Ephedrine has no current SAHPRA registration in South Africa, and formal safety labelling (warnings/contraindications) is a Blocking data gap — this alone precludes any near-term “Go” or “Proceed with Guardrails” decision. The supporting evidence for “Nasal Cavity Disease” is only L3-level (mostly non-pharmacological surgical/device trials plus historical, low-tier literature), with just one trial (NCT00562120) rated moderately relevant.
To proceed, the following is needed:
- Retrieval and review of SAHPRA/TFDA Professional Information (PI) for warnings, contraindications, and dosing (DG001, Blocking)
- Confirmed mechanism of action data from DrugBank (DG002, High)
- Relevance grading of the “pending” trials and literature records currently unassessed
- Clarification of any registration pathway or import mechanism if ephedrine-based nasal decongestant products are to be considered for the South African market
- A dedicated safety review given ephedrine’s known cardiovascular stimulant profile (relevant given its other low-evidence predicted indication, trigeminal autonomic cephalalgia, which carries a cardiovascular risk signal)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.